Source: MIL-OSI Submissions
Source: Cannasouth
Cannasouth has today signed a supplier agreement with WEECO Pharma GMBH based in Germany for the supply of cannabis flower from New Zealand into Europe.
The total value of the agreement could be worth between NZ$12 million and NZ$15 million over years two and three.
WEECO is one of the leading importers of medicinal cannabis in Germany. Under individual cultivar supply agreements to be negotiated, cannabis flower will be supplied to WEECO from Cannasouth’s world-class cannabis cultivation and processing facility based in Waikato, New Zealand.
Cannasouth CEO Mark Lucas says Cannasouth will benefit from the opportunity this agreement brings while it ramps up production and completes its Good Agricultural & Collection Practices (GACP) certification, which is expected soon.
“Good Manufacturing Practice (GMP) certification is next to complete and is necessary for higher-value flower sales. Accessing the European market also requires suitable genetics.
“Our agreement with WEECO means Cannasouth can now confidently move forward with our growing programme and begin the next phase of our cultivar on-boarding and development.”
Exporting medicinal cannabis flower has always been part of Cannasouth’s strategy for generating additional revenue streams, while it develops its own medicinal cannabis products for the New Zealand market.
“Global demand, particularly in Europe, has created an early revenue opportunity in the export of premium cannabis flower,” says Mark. “Our world-class, next-generation cannabis cultivation and processing facility was fully commissioned at the end of last year. This has enabled us to take advantage of the rapidly growing and lucrative pharmaceutical cannabis flower market.
“We have taken our time to select the best partner in Europe to represent Cannasouth and deliver our flower to one of the fastest-growing medicinal cannabis markets in the world.
“Despite global geopolitical and economic uncertainty, the medicinal cannabis industry continues to grow rapidly as patients worldwide seek alternatives to currently available treatments.
“We are thrilled to partner with WEECO and be a key part of their global network and growth plans. We have built a world class team and world-class cultivation facility here in New Zealand. These strong foundations are now enabling us to reap the rewards of our efforts and participate as a key player on the international stage.”
CEO of WEECO Pharma GmbH Boerge Diessel says, “We are incredibly excited to be starting our partnership with Cannasouth. After a long vetting and qualification process, we are now able to add the top New Zealand supplier to our group of selected producers and genetics collaborators.
“Our customers will benefit from Cannasouth’s excellent quality produced in its state-of-the-art facility. We will develop products together that will enable clear advances to be made in the treatment of various illnesses and thus offer patients a better quality of life.”
Cannasouth’s agreement with WEECO is for a three-year term. Under the agreement WEECO has the right of first refusal for each new cultivar developed by Cannasouth.
Cannasouth and WEECO have also agreed to work together to develop cannabis cultivars to best suit the needs of the European market.
Cannasouth will retain sufficient flower to supply the local New Zealand market, which will enable its medicinal cannabis products to be verified. This flower is expected to be a popular form of medicinal cannabis with New Zealand patients.
About WEECO Pharma GmbH
WEECO Pharma GmbH is one of the leading EU-GDP Medicinal Cannabis companies in Europe. The company was founded in Hildesheim in 2018 by Entrepreneur and businessman Tim Feike. With its unique business model to supply top grade medical cannabis from all over the world to more than 40 German Medical Cannabis Wholesalers, at affordable prices they became the first of its kind in Germany, using a “distribution hub” concept.
WEECO provides a trading network within the German industry, and exports products to 7 international destinations, as well as having their own R & D facility in Denmark where strains are being created with over 30% THC and genetically developed to the specific production needs of individual GACP/GMP companies.
WEECO is growing its group internationally with different market strategies for new genetics and cultivation processes. Their concept is easy, they simply take the best ingredients and optimise their and their supplier´s processes using a high-end digital quality management system.
About Cannasouth Limited
Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients’ health outcomes and improve their quality of life. Our products will be produced under GxP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd, and Midwest Pharmaceutics NZ Ltd.
For further information visit www.cannasouth.co.nz
